Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization diseases.
We are pursuing the development of therapeutics to address the underlying causes of these debilitating, rare diseases through our in-depth understanding of the biological pathways involved in mineralization. We’re leveraging the insights of the key role that the genes ENPP1 and ABCC6 play in the critical mineralization pathway. An abnormal mineralization occurs when there is a deficiency in ENPP1 and ABCC6. Our focus is developing a novel therapy to treat the rare diseases that are a consequence of ENPP1 and ABCC6 deficiencies.
Data Provided by Refinitiv. Minimum 15 minutes delayed.